Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Fears of global aluminum shortages intensify - 2Turning into a Distributed Writer: My Composing Process
- 35 Affordable Travel Destinations To Visit In South America
- 4Fundamental Home Exercise center Hardware: Amplify Your Exercises
- 5Figuring out the Business venture Code: The Response to Building an Effective Startup
- 2026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- At least 490 protesters killed in Iran, activists say
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- World leaders, rights groups react to COP30 climate deal
- The Best Web-based Courses for Expertise Improvement
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
